Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WebMD's Ties To 185,000 Doctors Could Boost Uptake Of Hand-Held Devices

Executive Summary

WebMD could receive a marketing boost for its hand-held devices from its relationship with 185,000 physicians through its Medical Manager Health Systems subsidiary.

You may also be interested in...



WebMD Thinks Big: Acquisitions, Medicare Rx May Define Role

WebMD sees the Medicare prescription drug benefit as an opportunity to define a broader role for the company in health care

WebMD Thinks Big: Acquisitions, Medicare Rx May Define Role

WebMD sees the Medicare prescription drug benefit as an opportunity to define a broader role for the company in health care

Pfizer Reps To Introduce MS/IBM Office Management Software To Physicians

Pfizer's sales force will introduce practice management software to physicians on behalf of a new company formed by Pfizer, Microsoft and IBM.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel